Angiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFα production.
Peter M Abadir, Jeremy D Walston, Robert M Carey, Helmy M Siragy
Index: J. Interferon Cytokine Res. 31(6) , 471-4, (2011)
Full Text: HTML
Abstract
Angiotensin subtype-1 receptor (AT(1)R) influences inflammatory processes through enhancing signal transducer and activator of transcription proteins 3 (STAT3) signal transduction, resulting in increased tumor necrosis factor-α (TNF-α) production. Although angiotensin subtype-2 receptor (AT(2)R), in general, antagonizes AT(1)R-stimulated activity, it is not known if AT(2)R has any anti-inflammatory effects. In this study, we tested the hypothesis that AT(2)R activation plays an anti-inflammatory role by reducing STAT3 phosphorylation and TNF-α production. Changes in AT(2)R expression, TNF-α production, and STAT3 phosphorylation were quantified by Western blotting, Bio-Plex cytokine, and phosphoprotein cellular signaling assays in PC12W cells that express AT(2)R but not AT(1)R, in response to the AT(2)R agonist, CGP-42112 (CGP, 100 nm), or AT(2)R antagonist PD-123319 (PD, 1 μm). A 100% increase in AT(2)R expression in response to stimulation with its agonist CGP was observed. Further, AT(2)R activation reduced TNF-α production by 39% and STAT3 phosphorylation by 83%. In contrast, PD decreased AT(2)R expression by 76%, increased TNF-α production by 84%, and increased STAT3 phosphorylation by 67%. These findings suggest that increased AT(2)R expression may play a role in the observed decrease in inflammatory pathway activation through decreased TNF-α production and STAT3 signaling. Restoration of AT(2)R expression and/or its activation constitute a potentially novel therapeutic target for the management of inflammatory processes.
Related Compounds
Related Articles:
2011-01-01
[BMC Cancer 11 , 274, (2011)]
2013-02-01
[Curr. Hypertens. Rep. 15(1) , 25-30, (2013)]
2009-12-15
[Neuroscience 164(3) , 1263-73, (2009)]
2009-03-01
[Am. J. Physiol. Heart Circ. Physiol. 296(3) , H745-55, (2009)]
2007-10-01
[J. Cardiovasc. Pharmacol. 50(4) , 372-9, (2007)]